Aura Biosciences (AURA) vs Immatics N.V. (IMTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aura Biosciences (AURA) has outperformed Immatics N.V. (IMTX) over the past year, gaining 26.3% versus a loss of 43.4%. Over five years, IMTX leads with a -48.6% price change compared with -69.6% for AURA. Immatics N.V. is the larger company by market cap ($878.6 million vs $715.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | IMTX |
|---|---|---|
| Share price | $6.87 | $5.77 |
| Market cap | $714.99M | $878.58M |
| 1-day change | -1.58% | -3.03% |
| YTD return | +26.06% | -45.05% |
| 1-year return | +26.29% | -43.43% |
| 5-year return | -69.63% | -48.57% |
| EPS (TTM) | $-1.59 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-106.19M | — |
| 52-week high | $9.54 | $12.41 |
| 52-week low | $4.73 | $5.72 |
| Distance from 52-week high | -27.95% | -53.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +141.63% | +176.78% |
| Average volume | 847.22K | 962.74K |
| Shares outstanding | 104.07M | 152.27M |
| Employees | 113 | 721 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AURA has outperformed IMTX by 69.7 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees
AURA vs IMTX FAQ
Which is bigger, Aura Biosciences or Immatics N.V.?
Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $714.99M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or IMTX?
AURA returned +26.29% over the past 12 months, compared with -43.43% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Immatics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.